Dispinseri, Stefania
Marzinotto, Ilaria
Brigatti, Cristina
Pirillo, Maria Franca
Tolazzi, Monica
Bazzigaluppi, Elena
Canitano, Andrea
Borghi, Martina
Gallinaro, Alessandra
Caccia, Roberta
Vercesi, Riccardo
McKay, Paul F.
Ciceri, Fabio
Piemonti, Lorenzo
Negri, Donatella
Cinque, Paola
Cara, Andrea
Scarlatti, Gabriella
Lampasona, Vito http://orcid.org/0000-0001-5162-8445
Funding for this research was provided by:
Ministero della Salute (COVID-2020-12371617)
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Program Project COVID-19 OSR-UniSR)
Horizon 2020 (681137)
North Atlantic Treaty Organization (G5817)
Article History
Received: 2 September 2021
Accepted: 28 November 2021
First Online: 9 January 2022
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study subjects belonged to the IRCCS Ospedale San Raffaele COVID-19 cohort study COVID-BioB (registered as ClinicalTrialsgov-NCT04318366) and approved by the IRCCS Ospedale San Raffaele Ethics Review Board (protocol 68/INT/2020) and to the COVID-BioB related immunological sub-study “Role of the immune response in the infection with SARS-CoV-2 and in the pathogenesis of COVID-19” (protocol number 34/INT/2020).
: Written informed consent was obtained from all individual participants included in the study.
: Not applicable.
: LP and VL have a patent pending that refers to polypeptides, nucleic acids, vectors, and host cells and their use in the diagnosis and/or treatment of COVID-19 infections. All other authors have declared that no conflict of interest exists.